Newly diagnosed T2N2b oral tongue cancer with a borderline resectable neck and a heavy smoking history
A 58-year-old man presents with a 3.5 cm left lateral oral tongue squamous cell carcinoma with 1.5 cm depth of invasion, fixed to the floor of mouth. He has a 2.5 cm level II lymph node with extracapsular extension suspected on MRI (irregular margins, stranding) and a 1 cm level III node. He smokes 1.5 packs/day and has COPD with FEV1 55% predicted. He has lost 8 kg in 3 months. Biopsy shows poorly differentiated SCC, p16 negative. PET-CT shows no distant disease. The multidisciplinary board debates upfront surgery with adjuvant chemoradiation versus induction chemotherapy followed by surgery, given the bulky nodal disease and borderline pulmonary reserve.
1. What staging information is most important to confirm before committing to a treatment sequence, and how would you justify the choice between upfront surgery and induction chemotherapy?
Read the worked answer
The key staging elements are the nodal burden and ECE status, not just the T category. Under AJCC 8th edition, a single ipsilateral node ≤3 cm is N1; multiple ipsilateral nodes ≤6 cm is N2b; and clinically evident ECE upgrades to N3b regardless of size. If ECE is truly present, this is stage IVB (T2N3bM0), which changes prognosis and the rationale for systemic therapy.
Confirm ECE with the best available imaging (contrast CT/MRI; PET-CT is not reliable for ECE) and consider FNA of the level II node. If ECE is confirmed, the standard of care remains upfront surgery with neck dissection followed by adjuvant chemoradiation (postoperative cisplatin + RT for ECE). Induction chemotherapy is not standard for resectable oral cavity SCC and does not improve survival; it may be considered only in a trial or to downstage borderline unresectable disease.
The pulmonary reserve (FEV1 55%) is a real constraint but does not make the cancer unresectable; it argues for careful anesthetic planning, possible postoperative ICU, and smoking cessation. The 8 kg weight loss warrants nutrition optimization (dietitian, consider feeding tube if intake is poor) before surgery. The decision should be made at a multidisciplinary board with the patient's goals documented.
2. How would you counsel the patient on the expected adjuvant treatment and the risks of a treatment sequence that includes both surgery and chemoradiation?
Read the worked answer
If ECE is confirmed, the expected adjuvant regimen is concurrent cisplatin with RT to 60–66 Gy to the primary bed and neck. This is based on the EORTC 22931 and RTOG 9501 trials, which showed improved locoregional control and disease-free survival with chemoradiation in high-risk patients (ECE and/or positive margins).
The counseling should cover:
- Surgical risks: bleeding, infection, airway compromise, fistula, shoulder dysfunction, and the need for reconstruction (free flap vs. local flap).
- Adjuvant risks: mucositis, dysphagia, xerostomia, osteoradionecrosis, and cisplatin nephrotoxicity/ototoxicity. With FEV1 55%, radiation pneumonitis and pulmonary complications are relevant.
- Functional outcomes: speech and swallowing changes; prehabilitation and swallowing therapy.
- Surveillance: clinical exam and imaging every 1–3 months for the first 2 years, then less frequently.
The patient should understand that the sequence is not a choice between equals - surgery plus adjuvant therapy is the standard for resectable disease with ECE, and induction chemotherapy is not a substitute.